| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Esperion Therapeutics, Inc. (ESPR) has 9 insiders with recent SEC Form 4 filings, including 6 buys and 13 sells. ESPR is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 1.47M | $4.65M | - | |
| CFO | 467.5K | $1.48M | - | |
| Other | 385.9K | $1.22M | - | |
| Other | 380.0K | $1.20M | - | |
| Dir | 177.5K | $561.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 7, 2018 | Biotech Target N V55 | 10% Owner | Buy | 60,000 | $37.79 | $2,267,292.00 | +2.0% | |
| Jun 5, 2018 | Biotech Target N V55 | 10% Owner | Buy | 60,000 | $38.47 | $2,308,440.00 | +2.0% | |
| May 21, 2018 | Biotech Target N V55 | 10% Owner | Buy | 130,000 | $40.11 | $5,213,770.00 | +2.3% | |
| Mar 29, 2018 | Newton Roger S | Director | Sell | 25,000 | $72.37 | $1,809,276.80 | -1.0% | |
| Jan 25, 2018 | Vitullo Nicole | Director | Sale+OE | 11,674 | $71.79 | $838,076.46 | -43.2% | |
| Dec 6, 2017 | Vitullo Nicole | Director | Sell | 9,326 | $53.85 | $502,205.10 | -26.5% | |
| Mar 22, 2017 | Goldstein Dov A Md | Director | Sell | 800,000 | $41.66 | $33,327,088.28 | -28.7% | |
| Mar 21, 2017 | Janney Daniel | Director | Sell | 350,000 | $45.80 | $16,029,262.91 | -4.6% | |
| Mar 21, 2017 | Omenn Gilbert S | Director | Buy | 1,000 | $42.26 | $42,260.00 | New | |
| Nov 1, 2016 | Lalwani Narendra D. | Chief Operating Officer | Buy | 5,000 | $9.93 | $49,650.00 | New |